✦ LIBER ✦

A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design

✍ Scribed by Michael Zile; William Gaasch; William Little; Gary Francis; Luigi Tavazzi; John Cleland; Martin Davies; For The MCC-135 GO1 Investigators

Book ID: 119212125
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 108 KB
Volume: 10
Category: Article
ISSN: 1532-8414
DOI: 10.1016/j.cardfail.2003.10.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study

✍ Ik-Kyung Jang; Veronica Pettigrew; Michael H. Picard; Peter R. Kowey; Valentin D 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 219 KB

A Phase II, Randomized, Double-Blind, Mu

A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure

✍ Runlin Gao; Jian Zhang; Liuquan Cheng; Xuesi Wu; Wei Dong; Xinchun Yang; Tiancha 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 798 KB

Design and Rationale of the LAPLACE-TIMI

Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy

✍ Payal Kohli; Nihar R. Desai; Robert P. Giugliano; Jae B. Kim; Ransi Somaratne; F 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB